OrigAMI-1

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

Jul 5, 2023 → Sep 18, 2026

Cited window

Sep 15, 2023 → Aug 13, 2026

Retrieved

Oct 31, 2026

Title

A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer

Registry

NCT05379595

Study IDs

CR109215 · 61186372GIC2002 (Janssen Research & Development, LLC) · 2021-006629-23 · 2023-506517-22-00 (EUCT number)

Sponsor

Janssen Research & Development, LLC

Design

Phase 1/Phase 2 · Interventional, non randomized, parallel

Status

Recruiting

Enrollment

225 estimated

Registered

2022-05-18

Start

2022-07-29 actual

Primary completion

2027-04-27 estimated

Primary endpoint

Cohorts A, B, and C: Objective Response Rate (ORR)

Interventions

6 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –Not yet captured in this edition: a view on pembrolizumab versus chemotherapy and crossover-related interpretation in MSI-high advanced or metastatic colorectal cancer.
• –Not yet captured in this edition: a view on orthogonal confirmation of mismatch-repair testing to avoid misclassification before metastatic colorectal cancer treatment.
• –Not yet captured in this edition: a view on alternative later-line treatment sequences guided by patient goals and discussion of risks and benefits.
• –Not yet captured in this edition: a view on dual-method mismatch-repair testing to avoid misclassification when selecting treatment for metastatic colorectal cancer.
• –Not yet captured in this edition: a view on confirming mismatch-repair immunohistochemistry with an orthogonal method to avoid misclassification before systemic-treatment selection.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –178 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
• –Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
• –Discussion coverage is incomplete. References that do not use the trial's recognized names or identifier, including different spellings, may be missing.
• –Some portions of longer discussions were not fully assessed for clinician views; potentially relevant testing and treatment-sequencing positions may therefore be absent. The referral discussion is not exhaustive: not every alternative trial and its prior-treatment conditions is described here.
• –Multiple podcast/video versions and reposts repeat material. Source counts cannot be interpreted as independent-HCP counts or consensus.
• –Some remarks cannot be assigned to a named speaker. A participant list, title, profile or publication authorship does not resolve who spoke those passages.
• –Some named public authors do not have an established clinical role in the sources reviewed. Organizational summaries and source-described roles or trial involvement are not independent confirmation of clinical credentials or independence.
• –The early-phase monotherapy population was highly selected, with small cohorts, early enrollment closure in two cohorts and possible survivor bias in the interval analysis. These constraints limit generalization and comparative interpretation.
• –Different reports concern monotherapy, chemotherapy combinations, different cohorts and different follow-up. Their response, durability and safety descriptions should not be pooled.
• –A speaker's right-sided CRC post and another speaker's future-studies interview do not name OrigAMI-1 and are treated as setting or development context, not as this trial's results.
• –Some source descriptions of treatment allocation, comparators and eligibility are not corroborated by the cited primary statements. They are preserved as what was said, not as validated study methods.
• –A full protocol and complete colorectal-cancer regulatory assessment were not available. This report does not establish exact current eligibility, entitlement to access or approved CRC use.

How reports are built and checked: Methods.

Last checked for new commentary Oct 31, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update. No corrections.

Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.

Help me decide whether to buy the Erudio report "OrigAMI-1" (NCT05379595), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.

1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "origami-1-05379595". If you cannot make requests, read https://www.erudio.com/reports/origami-1-nct05379595.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT05379595", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct05379595 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.

When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.

curl https://www.erudio.com/reports/origami-1-nct05379595.json
curl https://www.erudio.com/reports/origami-1-nct05379595.md

# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "origami-1-05379595" })